William M. Southerland to Humans
This is a "connection" page, showing publications William M. Southerland has written about Humans.
Connection Strength
0.184
-
Southerland WM, Swamidass SJ, Payne PRO, Wiley L, Williams-DeVane C. The diversity and disparity in biomedical informatics (DDBI) workshop. Pac Symp Biocomput. 2018; 23:614-617.
Score: 0.029
-
Mao L, Fang Y, Campbell M, Southerland WM. Population differentiation in allele frequencies of obesity-associated SNPs. BMC Genomics. 2017 Nov 10; 18(1):861.
Score: 0.029
-
Li H, Liu C, Burge L, Southerland W. Identification of two post-translational modifications via tandem mass spectrometry. Int J Comput Biol Drug Des. 2012; 5(3-4):314-24.
Score: 0.020
-
Hu JZ, Bai L, Chen DG, Xu QT, Southerland WM. Computational investigation of the anti-HIV activity of Chinese medicinal formula Three-Huang Powder. Interdiscip Sci. 2010 Jun; 2(2):151-6.
Score: 0.017
-
Hu ZJ, Bai L, Tizabi Y, Southerland W. Computational modeling study of human nicotinic acetylcholine receptor for developing new drugs in the treatment of alcoholism. Interdiscip Sci. 2009 Dec; 1(4):254-62.
Score: 0.017
-
Hedges JR, Soliman KFA, Southerland WM, D'Amour G, Fern?ndez-Repollet E, Khan SA, Kumar D, Shikuma CM, Rivers BM, Yates CC, Yanagihara R, Thompson WE, Bond VC, Harris-Hooker S, McClure SA, Ofili EO. Strengthening and Sustaining Inter-Institutional Research Collaborations and Partnerships. Int J Environ Res Public Health. 2021 03 08; 18(5).
Score: 0.009
-
Apprey V, Wang S, Tang W, Kittles RA, Southerland WM, Ittmann M, Kwabi-Addo B. Association of Genetic Ancestry With DNA Methylation Changes in Prostate Cancer Disparity. Anticancer Res. 2019 Nov; 39(11):5861-5866.
Score: 0.008
-
Ogindo CO, Khraiwesh MH, George M, Brandy Y, Brandy N, Gugssa A, Ashraf M, Abbas M, Southerland WM, Lee CM, Bakare O, Fang Y. Novel drug design for Chagas disease via targeting Trypanosoma cruzi tubulin: Homology modeling and binding pocket prediction on Trypanosoma cruzi tubulin polymerization inhibition by naphthoquinone derivatives. Bioorg Med Chem. 2016 08 15; 24(16):3849-55.
Score: 0.007
-
Zhao Y, Hao Y, Ji H, Fang Y, Guo Y, Sha W, Zhou Y, Pang X, Southerland WM, Califano JA, Gu X. Combination effects of salvianolic acid B with low-dose celecoxib on inhibition of head and neck squamous cell carcinoma growth in vitro and in vivo. Cancer Prev Res (Phila). 2010 Jun; 3(6):787-96.
Score: 0.004
-
Chen P, Liu C, Burge L, Li J, Mohammad M, Southerland W, Gloster C, Wang B. DomSVR: domain boundary prediction with support vector regression from sequence information alone. Amino Acids. 2010 Aug; 39(3):713-26.
Score: 0.004
-
Jackson PL, Scott KR, Southerland WM, Fang YY. Enaminones 8: CoMFA and CoMSIA studies on some anticonvulsant enaminones. Bioorg Med Chem. 2009 Jan 01; 17(1):133-40.
Score: 0.004
-
Fleming ES, Perkins J, Easa D, Conde JG, Baker RS, Southerland WM, Dottin R, Benabe JE, Ofili EO, Bond VC, McClure SA, Sayre MH, Beanan MJ, Norris KC. The role of translational research in addressing health disparities: a conceptual framework. Ethn Dis. 2008; 18(2 Suppl 2):S2-155-60.
Score: 0.004
-
Fleming ES, Perkins J, Easa D, Conde JG, Baker RS, Southerland WM, Dottin R, Benabe JE, Ofili EO, Bond VC, McClure SA, Sayre MH, Beanan MJ, Norris KC. Addressing health disparities through multi-institutional, multidisciplinary collaboratories. Ethn Dis. 2008; 18(2 Suppl 2):S2-161-7.
Score: 0.004
-
Das JR, Fryar-Tita EB, Zhou Y, Green S, Southerland WM, Bowen D. Sequence-dependent administration of 5-fluorouracil maintains methotrexate antineoplastic activity in human estrogen-negative breast cancer and protects against methotrexate cytotoxicity in human bone marrow. Anticancer Res. 2007 Nov-Dec; 27(6B):3791-9.
Score: 0.004
-
Fryar-Tita EB, Das JR, Davis JH, Desoto JA, Green S, Southerland WM, Bowen D. Raloxifene and selective cell cycle specific agents: a case for the inclusion of raloxifene in current breast cancer treatment therapies. Anticancer Res. 2007 May-Jun; 27(3B):1393-9.
Score: 0.003
-
Das JR, Fryar-Tita EB, Green S, Southerland WM, Bowen D. Sequence-dependent administration of raloxifene and 5-fluorouracil/pemetrexed protects against pemetrexed cytotoxicity in human bone marrow. Anticancer Res. 2007 Mar-Apr; 27(2):825-33.
Score: 0.003
-
Ammosova T, Berro R, Jerebtsova M, Jackson A, Charles S, Klase Z, Southerland W, Gordeuk VR, Kashanchi F, Nekhai S. Phosphorylation of HIV-1 Tat by CDK2 in HIV-1 transcription. Retrovirology. 2006 Nov 03; 3:78.
Score: 0.003
-
Das JR, Fryar EB, Green S, Southerland WM, Bowen D. The protection against trimetrexate cytotoxicity in human bone marrow by sequence-dependent administration of raloxifene, 5-fluorouracil/trimetrexate. Anticancer Res. 2006 Nov-Dec; 26(6B):4279-86.
Score: 0.003
-
Fryar EB, Das JR, Davis JH, Desoto JA, Laniyan I, Southerland WM, Bowen D. Raloxifene attenuation of 5-FU/methotrexate cytotoxicity in human breast cancer cells: the importance of sequence in combination chemotherapy. Anticancer Res. 2006 May-Jun; 26(3A):1861-7.
Score: 0.003
-
Das JR, Fryar EB, Epie NN, Southerland WM, Bowen D. Raloxifene attenuation of methotrexate cytotoxicity in human bone marrow by sequence-dependent administration of raloxifene, 5-FU/methotrexate. Anticancer Res. 2006 May-Jun; 26(3A):1877-83.
Score: 0.003
-
Ammosova T, Jerebtsova M, Beullens M, Lesage B, Jackson A, Kashanchi F, Southerland W, Gordeuk VR, Bollen M, Nekhai S. Nuclear targeting of protein phosphatase-1 by HIV-1 Tat protein. J Biol Chem. 2005 Oct 28; 280(43):36364-71.
Score: 0.003
-
De Soto JA, Bowen D, Davis JH, Southerland WM, Hawkins M. Sequence- and time-dependent antagonism between raloxifene and methotrexate in human breast cancer cells. Anticancer Res. 2002 Mar-Apr; 22(2A):1007-9.
Score: 0.002